Interest in exosomes within aesthetic dermatology and cosmetic practice has grown explosively in recent years. Exosomes are nanovesicles containing proteins, lipids, and nucleic acids that mediate intercellular communication and help regulate inflammation, extracellular matrix remodeling, and tissue regeneration. They are regarded as a “cell-free” alternative to stem cell therapies: a substantial part of the regenerative effects of cell-based technologies is thought to be mediated via secreted extracellular vesicles.

For the skin, which is constantly exposed to UV radiation, oxidative stress, chronic low-grade inflammation, and progressive degradation of the dermal matrix, this concept is particularly attractive. This has driven growing interest in topical products formulated with exosomes and in treatment protocols that combine exosome-based preparations with microneedling, radiofrequency microneedling, and other energy-based technologies.

A separate cluster of expectations is specifically linked to the potential rejuvenating effect of exosomes. In human clinical studies, exosome--based treatments have been associated with short‑term improvements in hydration, elasticity, wrinkle severity, pore appearance, pigmentation, and overall skin quality. Some trials reported changes compatible with a “cell-free biorevitalization” concept: increased dermal density, thickening of collagen fibers, reinforcement of the elastic fiber network, and signs of extracellular matrix remodeling on histology and molecular profiling.

Exactly at this point, however, the key problem becomes apparent. The clinical evidence for exosome-based products in skin rejuvenation remains lagging behind marketing claims. Most studies are small, short-term, non-randomized, and inadequately controlled, with heterogeneous endpoints and measurement tools. This prevents us from treating exosomes as a technology with a predictable, long-term rejuvenating effect.

Why a systematic review was needed and how it was done

The authors of the systematic review published in early 2026 in Cureus set out to comprehensively evaluate the efficacy and safety of exosome-based therapies for skin rejuvenation in humans and to identify gaps in current knowledge [1]. They conducted a systematic search in PubMed, Scopus, Cochrane Library, and Web of Science covering the period from 2000 to late 2025, following the PRISMA 2020 guideline [2].

Eligibility criteria were structured according to the PICO framework. The review included adult populations undergoing aesthetic or dermatologic procedures aimed at skin rejuvenation. Interventions were exosome-based or, more broadly, exosome-oriented therapies, used either as monotherapy or as an adjunct to standard dermatologic procedures. Different types of comparators were allowed: no treatment, placebo, standard care, or alternative procedures. Outcomes included objective and subjective measures of rejuvenation (wrinkles, elasticity, texture, pigmentation, hydration) as well as safety.

Only full-text, peer-reviewed human studies in English were included. In vitro and animal studies, reviews, single case reports, conference abstracts, and papers focusing exclusively on wound or scar management without a clear aesthetic rejuvenation component were excluded. Commercially driven trials with insufficiently transparent methodologies were also excluded to maintain clinical relevance and scientific rigor.

Study selection and data extraction were performed by two independent reviewers, with disagreements resolved by a third expert. Risk of bias in non-randomized studies of interventions was assessed using the ROBINS-I tool, followed by visualizing the results [3].

What the clinical data actually show

Nineteen studies met the inclusion criteria. Most were non-randomized: single-arm or multi-arm before-and-after designs, split-face comparisons, and uncontrolled clinical series. Sample sizes ranged from 3 to 95 participants, with a predominance of middle-aged women. Main indications included photoaging and chronological aging of the face, as well as texture irregularities and uneven skin tone.

Exosome sources varied widely: mesenchymal stem cells derived from adipose tissue, placental MSCs, preparations enriched in platelet-derived exosomes from human platelet extract, milk-derived vesicles, and plant-derived and microbial vesicles (e.g., exosomes from lactic acid bacteria). Some protocols used autologous extracellular vesicles isolated from the participants’ own plasma.

Delivery formats included:

• topical serums and creams applied at home once or twice daily;
• combinations of microneedling or radiofrequency microneedling with immediate application of exosome-based preparations;
• mesotherapy-like injections and other intradermal techniques.
• Outcomes were assessed using contemporary tools: 3D imaging and photoanalysis (VISIA, Antera 3D, PRIMOS), corneometry, cutometry, tewametry, high‑frequency ultrasound, along with validated clinical scales and patient-reported satisfaction scores.

Despite pronounced methodological heterogeneity, the overall direction of the results was similar. Over 2–12 weeks, many studies reported:

• improved hydration and barrier function;
• increased elasticity;
• reductions in wrinkle number and area;
• decreased appearance of pores;
• more even skin tone with less photodamage and mottled pigmentation;
• Higher subjective satisfaction with appearance.

In studies that included histologic and molecular analyses, investigators observed thickening of collagen fibers, increased dermal density, and shifts in the expression of genes and proteins related to the extracellular matrix and aging. These changes included reduced markers of cellular senescence and modulation of the senescence-associated secretory phenotype (SASP).

Data from split-face protocols are particularly illustrative: when applied after microneedling, topical exosome-based products produced clinical outcomes comparable to those of PRP (platelet-rich plasma) and PRFM (platelet-rich fibrin matrix) in photo-rejuvenation. They did not show clear superiority but functioned as a full-fledged alternative in the short term.

Safety: what we know and where the risks are

The review devotes a separate section to safety. In controlled studies using regulated, certified products, tolerability was generally favorable. The most common adverse events were short-lived erythema, edema, discomfort, and dryness, related to both the procedures themselves and topical therapy. No serious systemic adverse events were reported.

However, the review also includes a case series in which poorly characterized exosome formulations were injected intradermally without proper medical supervision. Patients developed persistent nodules, erythema, chronic inflammation, and scarring that required prolonged treatment. These observations highlight that exosome-based interventions are not “safe by default” and that safety strongly depends on product quality, route of administration, and adherence to clinical standards.

Limitations of the current evidence and practical value of the review

The authors clearly acknowledge the limitations of the available evidence. Most included studies are non-randomized, have small sample sizes, and lack long-term follow-up, increasing the risk of bias and making causal interpretation difficult. Exosomes were derived from multiple sources, using different isolation and characterization methods, and were administered at varying doses and treatment regimens, making cross-study comparison challenging.

Outcomes and assessment tools also differed substantially, ranging from objective instrumental measurements to satisfaction questionnaires and visual ratings, with no robust statistical analysis. Reporting of adverse events was often incomplete, and active safety monitoring was not consistently implemented.

Even so, the review is highly valuable for practitioners. It consolidates scattered data, outlines common trends in efficacy and safety, reminds readers about the real limitations of the evidence, and underscores the need for cautious interpretation. For clinicians, this provides a solid basis for more balanced communication with patients: it becomes easier to explain that exosome-based products can deliver short-term improvements in key skin parameters, while long-term outcomes and optimal protocols remain unclear.

What this means for everyday practice

Several practical takeaways emerge from this systematic review [1].

First, exosome-based preparations do show consistent short-term improvements in hydration, elasticity, texture, pore size, pigmentation, and overall skin appearance when used in rejuvenation protocols.

Second, these effects are currently supported mainly by small, heterogeneous, short-term studies, so it is premature to promise predictable, long-lasting “rejuvenation”.

Third, in topical and adjuvant use under controlled conditions, the safety profile looks favorable, but reported complications with unregulated injectable formulations underscore the need to use only well-defined products and protocols. In practice, this means:

• choosing products with transparent origin and characterization of exosomes;
• using exosome-based treatments as an adjunct to established, evidence-based protocols rather than a complete replacement;
• avoiding off-label injectable use of poorly characterized products;
• openly discussing the limitations of the current evidence base with patients.

In conclusion, exosome-based approaches to skin rejuvenation are in an active stage of development. Short-term clinical data are encouraging and support the biological potential of exosomes as a cell-free regenerative tool. At the same time, methodological heterogeneity, limited sample sizes and follow-up, and incomplete safety reporting do not yet allow exosomes to be considered a “new standard” in aesthetic dermatology. For practitioners, this is a signal to combine genuine interest in the technology with a critical mindset and to rely on real data from systematic reviews rather than on marketing narratives.

Reference

1. Flores Rodriguez J.C., Toledo Avelar L.E, Yi K. et al. Efficacy of exosome-based therapies for skin rejuvenation: a systematic review of human studies. Cureus. 2026; 18(2): e104182.
2. Page M.J., McKenzie J.E., Bossuyt P.M. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
3. Sterne J.A.C., Savović J., Page M.J. et al. RoB 2 and ROBINS-I: tools for assessing risk of bias in randomized and non-randomized studies. BMJ 2019; 366: l4898.